US009408898B2

(12) **United States Patent**
Seavey et al.

(10) **Patent No.: US 9,408,898 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **COMPOSITIONS COMPRISING ANGIOGENIC FACTORS AND METHODS OF USE THEREOF**

(71) Applicant: **The Trustees of the University of Pennsylvania**, Philadelphia, PA (US)

(72) Inventors: **Matthew Seavey**, Secane, PA (US); **Yvonne Paterson**, Philadelphia, PA (US); **Paulo Maciag**, Northbrook, IL (US); **Duane Sewell**, Cheltenham, PA (US)

(73) Assignee: **THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA**, Philadelphia, PA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/304,689**

(22) Filed: **Jun. 13, 2014**

(65) **Prior Publication Data**

US 2015/0079034 A1 Mar. 19, 2015

Related U.S. Application Data

(62) Division of application No. 13/254,607, filed as application No. PCT/US2010/026257 on Mar. 4, 2010, now Pat. No. 8,778,329.

(60) Provisional application No. 61/157,367, filed on Mar. 4, 2009.

(51) **Int. Cl.**

A61K 39/00	(2006.01)
C07K 14/47	(2006.01)
C07K 14/71	(2006.01)
A61K 45/06	(2006.01)
C07K 14/195	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 39/0011*** (2013.01); ***A61K 45/06*** (2013.01); ***C07K 14/195*** (2013.01); ***C07K 14/4748*** (2013.01); ***C07K 14/71*** (2013.01); *A61K 2039/522* (2013.01); *A61K 2039/523* (2013.01); *A61K 2039/53* (2013.01); *A61K 2039/6037* (2013.01); *A61K 2039/6068* (2013.01); *C07K 2319/55* (2013.01)

(58) **Field of Classification Search**

CPC A61K 39/0011

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,683,195	A	7/1987	Arnheim et al.
6,773,900	B2	8/2004	Short et al.
6,855,320	B2	2/2005	Paterson
7,094,410	B2	8/2006	Reisfield et al.
7,662,396	B2	2/2010	Paterson et al.
8,241,636	B2	8/2012	Paterson et al.
8,268,326	B2	9/2012	Paterson et al.
8,337,861	B2	12/2012	Paterson et al.
2004/0033493	A1	2/2004	Tchernev et al.
2005/0175624	A1	8/2005	Romero et al.
2005/0281783	A1	12/2005	Kinch et al.
2006/0210540	A1	9/2006	Paterson et al.
2007/0154953	A1	7/2007	Brunner et al.
2007/0207171	A1	9/2007	Dubensky et al.
2007/0264279	A1	11/2007	Gravekamp et al.
2008/0131456	A1	6/2008	Paterson

FOREIGN PATENT DOCUMENTS

EP	1408048		4/2004
WO	WO 92/09300		6/1992
WO	WO 96/14087		5/1996
WO	WO 01/72329	A1	10/2001
WO	WO 03/073826	*	9/2003
WO	WO 03/073995		9/2003
WO	WO 2005/037233		4/2005
WO	WO 2006/017856		2/2006
WO	WO 2006/036550		6/2006
WO	WO 2007/004060		1/2007
WO	WO 2008/079172		7/2008
WO	WO 2010/040135		4/2010

OTHER PUBLICATIONS

Dominiecki et al. "Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors" Cancer Immunol. Immunother. 54(5):477-88. May 2005.

Beatty et al. "IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma" J Immunol. 15; 166(4):2276-85. Feb. 2001.

Domenech et al. "Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin" The Journal of Immunology, Nov. 15, vol. 155 No. 10 4766-4774, (1995).

Mata et al. "Evaluation of recombinant Listeria monocytogenes expressing an HIV protein that protects mice against viral challenge" Vaccine. 19:1435-45. (2001).

Boyer et al. "DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication" Virology. ;333(1):88-101. Mar. 1, 2005.

Sun et al. "Isolation of Listeria monocytogenes small-plaque mutants defective for intracellular growth and cell-to-cell spread" Infect Immun; 58(11):3770-3778. Nov. 1990.

Lauer et al. "Construction, Characterization, and Use of Two Listeria monocytogenes Site-Specific Phage Integration Vectors" Journal of Bacteriology, p. 4177-4186. Aug. 2002.

(Continued)

Primary Examiner — Albert Navarro

(74) *Attorney, Agent, or Firm* — Pearl Cohen Zedek Latzer Baratz LLP

(57) **ABSTRACT**

The present invention provides recombinant *Listeria* strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a PEST-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.

28 Claims, 30 Drawing Sheets